Enzymatica AB: Enzymatica announces a study showing the ability of ColdZyme to deactivate major common cold viruses
November 14 2017 - 6:02AM
Press release
14 November, 2017
Enzymatica announces a study
showing the ability of ColdZyme to deactivate major common cold
viruses
Enzymatica announced today a
publication in a peer-reviewed journal presenting the results of an
in vitro study showing the ability of
ColdZyme® Mouth Spray to deactivate the majority of viruses that
cause the common cold. The study demonstrated that ColdZyme
deactivated the viruses tested and prevented viral-induced
cytopathic effect by 64.5 % to 99.9 %. These results indicate that
ColdZyme might have clinical benefits in prevention and treatment
of the common cold.
The medical device ColdZyme is a mouth spray that
forms a barrier in the throat against common cold viruses. The
barrier solution of the device is composed of glycerol and Atlantic
cod trypsin. The study was conducted by an independent, accredited
and certified laboratory. The goal of the study was to determine
the ability of ColdZyme to deactivate several viruses known to
cause the common cold in humans. A virucidal efficacy suspension
test was conducted using ColdZyme against viruses belonging to the
four virus families known to cause the majority of common
colds1. ColdZyme
deactivated rhinovirus type 1A by 91.7 %, rhinovirus type 42 by
92.8 %, human influenza A virus H3N2 by 96.9 %, respiratory
syncytial virus (RSV) by 99.9 % and adenovirus type 2 by 64.5 %.
Furthermore, cytotoxicity was not detected at any dilution or cell
line tested.
"The results indicate that ColdZyme can offer a
protective barrier against most common cold viruses, known to cause
the disease. This is also supported by our previous clinical study,
COLDPREV2, and our open
label studies," says Fredrik Lindberg, CEO of Enzymatica.
The in vitro study was based
on a standardised and validated methodology adapted to mimic the
environment in vivo in the oropharynx (mouth
and throat) where viruses take hold, invade and cause the
disease.
The basis for the use of ColdZyme against the
common cold is thought to partly depend on the ability of trypsin
in cleaving proteins on the surface of viruses important for
infection. This will inhibit viruses in binding to cellular
receptors, thereby preventing or stopping the proliferation of an
infection.
1) Stefansson,
B., Gudmundsdottir, Á. and Clarsund, M. (2017). A medical device
forming a protective barrier that deactivates four major common
cold viruses. Virology: Research & Reviews, 1
(5). doi:10.15761/VRR.1000130
2)COLDPREV:
https://doi.org/10.4236/ojrd.2017.74013
The information in this press release is
information that Enzymatica is obliged to make public pursuant to
the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
below, at 13:00 CET on November 14, 2017
For
more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a life science company that
develops and sells medical devices for infection-related diseases.
The products are based on a barrier technology that includes marine
enzymes. The Company's first product is ColdZyme® Mouth Spray,
which can prevent colds and reduce the duration of disease. The
product has been launched in around ten markets. The strategy is to
continue to grow by strengthening the Company's position in
existing markets and expanding into new geographic markets through
established partners. The company is headquartered in Lund and is
listed on Nasdaq First North. For more information please
visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser
Bank.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Sep 2024 to Oct 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Oct 2023 to Oct 2024